[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336735-105":59,"doc-detail-336735-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cancer-survival-statistics-in-china-2019-2021-a-multicenter-population-based-study","Cancer survival statistics in China 2019-2021 - a multicenter, population-based study","","A nationwide milestone in the Healthy China Program (2019–2030) targets 5-year cancer survival at 43.3% for all cancers combined by 2022. To evaluate progress, updated 5-year relative survival for 2019–2021 was analyzed for all cancers combined and 25 specific cancer types in China. Standardized registry data across 32 provincial regions covered 6,410,940 newly diagnosed patients with follow-up vital status through Dec 2021.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-survival-statistics-in-china-2019-2021-a-multicenter-population-based-study/336735/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-survival-statistics-in-china-2019-2021-a-multicenter-population-based-study/336735.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main goal of analyzing cancer survival from 2019 to 2021?","Question",{"text":113,"@type":114},"To assess progress toward the Healthy China Program target for 5-year cancer survival by evaluating updated survival for all cancers and 25 specific cancer types in China.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were survival estimates calculated in the study?",{"text":118,"@type":114},"The study used standardized data collection and quality control across cancer registries and estimated age-standardized 5-year relative survival overall and by cancer site, age group, and diagnosis period.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the key survival findings for 2019–2021?",{"text":122,"@type":114},"Age-standardized 5-year relative survival for all cancers combined was 43.7%. Survival varied widely by cancer type, from 8.5% for pancreatic cancer to 92.9% for thyroid cancer.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},336735,1790142600,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Journal of the National Cancer Center 4 (2024) 203–213  \nContents lists available at ScienceDirect  \nJournal of the National Cancer Center  \njournal [homepage:](homepage: www.elsevier.com/locate/jncc)[ www.elsevier.com/locate/jncc](homepage: www.elsevier.com/locate/jncc)  \n| Full Length Article |  |  |  |\n| --- | --- | --- | --- |\n| Cancer survival statistics in China 2019–2021: a multicenter, population-based study☆ |  |  | |\n| Hongmei Zeng1, Rongshou Zheng1, Kexin Sun1, Maigeng Zhou2, Shaoming Wang1, Li Li 1, Ru Chen1, Bingfeng Han1, Meicen Liu1, Jinhui Zhou1, Mengyuan Xu1, Lijun Wang2, Peng Yin2, Baohua Wang2, Jinling You2, Jing Wu2,∗, Wenqiang Wei 1,∗, Jie He 1,∗\u003Cbr>1 National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China\u003Cbr>2 National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China |  |  |  |\n| a r t i c l e i n f o |  | a b s t r a c t |  |\n| Keywords:\u003Cbr>Cancer survival Healthy China 2030 Population-based Policy evaluation China |  | Background: A milestone goal of the Healthy China Program (2019–2030) is to achieve 5-year cancer survival at 43.3% for all cancers combined by 2022. To assess the progress towards this target, we analyzed the updated survival for all cancers combined and 25 speciﬁc cancer types in China from 2019 to 2021.\u003Cbr>Methods: We conducted standardized data collection and quality control for cancer registries across 32 provinciallevel regions in China, and included 6,410,940 newly diagnosed cancer patients from 281 cancer registries during 2008–2019, with follow-up data on vital status available until December 2021. We estimated the age-standardized 5-year relative survival overall and by site, age group, and period of diagnosis using the International Cancer Survival Standard Weights, and quantiﬁed the survival changes to assess the progress in cancer control.\u003Cbr>Results: In 2019–2021, the age-standardized 5-year relative survival for all cancers combined was 43.7%(95% conﬁdence interval [CI], 43.6–43.7). The 5-year relative survival varied by cancer type, ranging from 8.5%(95% CI, 8.2–8.7) for pancreatic cancer to 92.9%(95% CI, 92.4–93.3) for thyroid cancer. Eight cancers had 5-year survival of over 60%, including cancers of the thyroid, breast, testis, bladder, prostate, kidney, uterus, and cervix. The 5-year relative survival was generally lower in males than in females. From 2008 to 2021, we observed signiﬁcant survival improvements for cancers of the lung, prostate, bone, uterus, breast, cervix, nasopharynx, larynx, and bladder. The most signiﬁcant improvement was in lung cancer.\u003Cbr>Conclusions: Progress in cancer control was evident in China. This highlights the importance of a comprehensive approach to control and prevent cancer. |  |\n\n1. Introduction  \nCancer is the second leading cause of death in China and accounts for more than 20% of national deaths. The prevention and control of cancer is a key component of the Healthy China initiative. Populationbased cancer survival is an indicator of the eﬀectiveness of eﬀorts in cancer control at the population level.1 Over the past decades, the State Council of China has released a series of national health plans, includingthe Medium-to-Long-Term Plan for Prevention and Control of Chronic Diseases in China (2017–2025), Healthy China 2030, and the Healthy China Program (2019–2030).2–4 Improvement in cancer survival has been among the most important national targets in the national health  \nplan, stated as “achieving 5-year survival for all cancers combined at 43.3% by 2022 and 46.6% by 2030 through enhancing cancer prevention and treatment system” in the Healthy China Program (2019– 2030). Especially following the publication of the Healthy China Program (2019–2030), the Chinese Government released the corresponding Cancer Prevention and Control A","cbCaicMkra6MdN0J","https://ap.wps.com/l/cbCaicMkra6MdN0J","pdf",1221705,11,"English","# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What was the main goal of analyzing cancer survival from 2019 to 2021?\",\"answer\":\"To assess progress toward the Healthy China Program target for 5-year cancer survival by evaluating updated survival for all cancers and 25 specific cancer types in China.\"},{\"question\":\"How were survival estimates calculated in the study?\",\"answer\":\"The study used standardized data collection and quality control across cancer registries and estimated age-standardized 5-year relative survival overall and by cancer site, age group, and diagnosis period.\"},{\"question\":\"What were the key survival findings for 2019–2021?\",\"answer\":\"Age-standardized 5-year relative survival for all cancers combined was 43.7%. Survival varied widely by cancer type, from 8.5% for pancreatic cancer to 92.9% for thyroid cancer.\"}]","Cancer survival statistics in China 2019-2021 - a multicenter, population-based study | PDF",1790016404,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8fb01d96ef20c0996b205f40fd1b23a0.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a08518b640281c9093f6956a26310157.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8e169b0dee410117d9fea2434f0c234.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1256ed50b034668a8a99eaf3913b88be.webp",980,1306]